Page 3 - Derek Chew News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Over the long term, surgery offers quality-of-life and mortality benefits “for a reasonable up-front cost,” a researcher says.

May 27, 2021 Adding dapagliflozin to standard heart failure therapies provides “intermediate value” for American patients who have heart failure with reduced ejection fraction (HFrEF), a new cost-effectiveness analysis suggests—at odds with earlier analyses that suggested the cost per quality-adjusted life-year (QALY) would be below the accepted $50,000 cutoff. That’s because earlier studies, focused on settings outside the United States, considered both the “markedly lower” costs of the drug in countries like the United Kingdom, Germany, and Spain, as well as the lower overall he...

 E-Mail Using more sensitive and frequent repeat testing of a blood test that indicates heart injury to guide the treatment of low-risk patients with symptoms of a possible heart attack resulted in patients being discharged earlier and receiving fewer cardiac stress tests but did not improve patient outcomes after one year, according to research presented at the American College of Cardiology's 70th Annual Scientific Session. In fact, a subset of patients receiving this more sensitive and frequent blood testing protocol were more likely to have a heart attack or to die during the one-year fo...